Synthetic Ovulation Stimulants Market
Number of pages: 100 | Report Format: PDF | Published date: June 20, 2023
Historical Years – 2021 | Base Year – 2022 | Forecasted Years – 2023-2031
|
Report Attribute |
Details |
|
CAGR |
5.97% |
|
Base Year for Estimation |
2022 |
|
Forecast Period |
2023 to 2031 |
|
Historical Year |
2021 |
|
Segments Covered |
Drug Class, Distribution Channel, and Region |
|
Regional Scope |
North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa |
According to the deep-dive market assessment study by Growth Plus Reports, the global synthetic ovulation stimulants market is expected to register a revenue CAGR of 5.97 % in the forecast period from 2022 to 2031.
Synthetic Ovulation Stimulants Market Fundamentals
Synthetic ovulation stimulants are commonly used in reproductive medicine to advance and control ovulation in females. These medications help treat infertility by stimulating the development of multiple follicles and promoting the release of eggs from the ovaries. They are commonly used in assisted reproductive technologies, such as in vitro fertilization (IVF) and intrauterine insemination (IUI).
The demand for synthetic ovulation stimulants is increasing due to various factors, including delayed childbearing, higher infertility rates, and the wider acceptance of assisted reproductive technologies around the world. Additionally, there is a growing inclination towards personalized medicine in reproductive health. With the help of technological progress and a better understanding of the female reproductive system, healthcare professionals now customize the dosage and treatment protocols of synthetic ovulation stimulants according to the unique features and requirements of each patient.
Additionally, the synthetic ovulation stimulants market offers numerous opportunities for revenue growth in the upcoming years. Pharmaceutical companies are currently investing in research and development to produce new formulations of synthetic ovulation stimulants that provide enhanced efficacy, convenience, and patient compliance. They are exploring various delivery methods, including subcutaneous injections and oral formulations, to achieve it.
Market players are investing in patient support programs and educational initiatives to increase awareness about infertility treatments and the role of synthetic ovulation stimulants. This includes providing resources, counseling services, and online platforms to support patients throughout their treatment journey. Moreover, Companies are focusing on expanding their presence in emerging markets where there is a growing demand for infertility treatments. This involves establishing distribution networks, conducting awareness campaigns, and collaborating with local healthcare providers.
Synthetic Ovulation Stimulants Market Dynamics
The key factor driving the synthetic ovulation stimulants market is the increasing incidences of hormonal disorders such as polycystic ovary syndrome (PCOS), and menstrual disorders. Polycystic ovary syndrome is a common hormonal disorder affecting women of reproductive age. It often leads to irregular or absent ovulation. According to the World Health Organization (WHO), around 116 million, or 3.4% of women globally are impacted by polycystic ovary syndrome. In addition, menstrual disorders such as heavy bleeding, painful periods, and irregular cycles also contribute to the demand for synthetic ovulation stimulants. According to the National Center for Biotechnology Information (NCBI), a typical menstrual cycle for women falls between 21 and 35 days. However, a significant percentage of women, ranging from 14% to 25%, experience irregular menstrual cycles, which can be either shorter or longer than the norm.
In recent years, assisted reproductive technologies like in vitro fertilization and intrauterine insemination have made significant progress. These methods rely on synthetic ovulation stimulants to regulate and induce ovulation in women seeking fertility treatments. With the continuous improvement and development of ART techniques, their success rates have increased, resulting in greater reliance on synthetic ovulation stimulants and a subsequent rise in revenue share.
Furthermore, manufacturers of synthetic ovulation stimulants are trying to increase their revenue share by implementing effective market access and expansion strategies. They are achieving it by expanding their product availability and distribution networks in both established and emerging markets, seeking regulatory approvals, forging partnerships with healthcare providers and clinics, and investing in marketing and promotional activities. These efforts are expected to result in a wider customer base and increased adoption of synthetic ovulation stimulants, ultimately leading to higher revenue shares for the manufacturers.
Restraining factors in the synthetic ovulation stimulants market include the high cost of treatment and the side effects. The cost of synthetic ovulation stimulants can be prohibitive for many patients, particularly those without insurance coverage or with high deductibles.
Market Ecosystem
The global synthetic ovulation stimulants market is analyzed from the following perspectives: by drug class, distribution channel, and region.
Synthetic Ovulation Stimulants Market by Drug Class
Based on drug class, the global synthetic ovulation stimulants market is segmented into clomiphene citrate (cc), aromatase inhibitors, GnRH analogs, gonadotropins, and human chorionic gonadotropin (hCG).
The clomiphene citrate (cc) segment accounted significant share of the global synthetic ovulation stimulants market revenue share in 2022. This is because clomiphene citrate is widely used as a first-line treatment for ovulation induction in women with polycystic ovary syndrome (PCOS) and other ovulation disorders. Additionally, the ease of availability and affordability of clomiphene citrate compared to other synthetic ovulation stimulants is driving its adoption in the market. In addition, leading manufacturers are prioritizing the development of cutting-edge formulations for clomiphene citrate and releasing generic versions with enhanced effectiveness and safety features. This is driving revenue growth for the synthetic ovulation stimulants market segment dedicated to clomiphene citrate.
Synthetic Ovulation Stimulants Market by Distribution Channel
Based on the distribution channel, the global synthetic ovulation stimulants market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies.
The hospital pharmacies segment accounts for most of the global synthetic ovulation stimulants market share. This is because of the high demand for synthetic ovulation stimulant drugs in fertility treatments and assisted reproductive technologies. In addition, the increasing prevalence of infertility and the growing adoption of in - vitro fertilization procedures are expected to further drive the growth of the hospital pharmacies segment in the coming years. Moreover, the retail pharmacies segment is anticipated to witness significant revenue growth owing to the rising availability of these drugs over the counter and the increasing awareness about fertility treatments among the general population.
The retail pharmacies segment is expected to show high revenue growth in the forecast years. Retail pharmacies offer convenience and accessibility to consumers, making it easier for them to purchase ovulation stimulant drugs without the need for a prescription. Moreover, the rising awareness about the benefits of ovulation stimulants and the availability of a wide range of products in retail pharmacies are also expected to drive the growth of this segment.
Synthetic Ovulation Stimulants Market by Region
Based on the region, the synthetic ovulation stimulants market is segmented into North America, Europe, Asia Pacific, Latin America, & the Middle East & Africa.
North America accounted for most of the global synthetic ovulation stimulants market in 2022. This trend is expected to continue in the coming years, driven by increasing awareness about infertility treatments and rising demand for assisted reproductive technologies. The availability of advanced healthcare infrastructure and high healthcare spending in the region are also contributing to the growth of the synthetic ovulation stimulants market. Additionally, the presence of a high number of women suffering from hormonal disorders such as PCOS, and irregular menstrual cycles can increase the demand for synthetic ovulation stimulant drugs in the forecast years. The Centers for Disease Control and Prevention estimates that PCOS is a common cause of female infertility, affecting around 6% to 12% (up to 5 million) of women in the United States who are of reproductive age in 2022.
The Asia Pacific synthetic ovulation stimulants market is projected to grow significantly in the forecast years. This growth is primarily attributed to the increasing prevalence of infertility and the rising demand for assisted reproductive technologies (ART) in the region.
Additionally, the growing awareness about the availability of these treatments and the advancements in the field of reproductive medicine is further expected to drive market revenue growth. The increasing number of infertility cases among women due to lifestyle changes, delayed pregnancies, and other medical conditions such as polycystic ovary syndrome (PCOS) is also anticipated to boost the demand for synthetic ovulation stimulants in the Asia Pacific region.
Synthetic Ovulation Stimulants Market Competitive Landscape
The synthetic ovulation stimulants market is highly competitive, with a number of key players vying for market share. Some of the major players in the market include Merck & Co., Inc., Ferring Pharmaceuticals, Inc., and Pfizer Inc. These companies have established themselves as leaders in the market through a combination of innovative products, strong distribution networks, and effective marketing strategies. However, the market is also characterized by a number of smaller players who are looking to carve out a niche for themselves by offering specialized products or services.
Some of the prominent companies having the largest revenue share in the global synthetic ovulation stimulants market are,
Synthetic ovulation stimulants are medications that are used to help women who are struggling to conceive. These drugs work by stimulating the ovaries to produce more eggs than they would naturally.
The global synthetic ovulation stimulants market has been growing steadily over the years. This growth can be attributed to factors such as an increase in the prevalence of hormonal disorders such as PCOS.
The global synthetic ovulation stimulants market is expected to register a revenue CAGR of 5.97% in the forecast period from 2022 to 2031.
North America accounted for the majority of the global synthetic ovulation stimulants market, with the majority of market revenue share in 2022. this is due to the presence of a high patient pool and the presence of many top market players.
Asia Pacific can be considered the key growth region due to the surge in patient count and the increasing introduction of new drugs in the market.
*Insights on financial performance are subject to the availability of information in the public domain